DBV estimates peanut allergy drug submission in Q3, but it may be too little too late in race with Aimmune
DBV Technologies has all but solidified its runner up status in the race to bring a peanut allergy treatment on to the United States market. The French drug developer on Wednesday said it would resubmit an application to market its product — Viaskin Peanut — in the third quarter, after withdrawing its application late last year in response to FDA concerns about the state of manufacturing and quality control data submitted. Meanwhile, arch rival Aimmune’s treatment AR101 is currently under FDA review.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.